Abstract. We determined the action mechanism of cordycepin, a major bioactive component of Cordyceps militaris, on responses of rat aortic smooth muscle cells (RASMCs) and on vascular disorders, especially neointimal formation. Cordycepin inhibited platelet-derived growth factor-BB (PDGF-BB)-induced RASMCs migration and proliferation in a dose-dependent manner. However, pre-treatment with N ω -nitro-L-arginine methyl ester, a nitric oxide synthase (NOS) inhibitor, and 1,3-dipropyl-8-sulphophenylxanthine (DPSPX), an A 1 / A 2 adenosinereceptor antagonist, abolished the inhibitory role of cordycepin. Cordycepin suppressed the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK) and heat shock protein 27 (Hsp27), but not that of extracellular signal-regulated kinase (ERK) 1/2 in RASMCs stimulated by PDGF-BB. The production of reactive oxygen species (ROS), O 2 − and H 2 O 2 , induced by PDGF-BB was abolished by the treatment of cordycepin. Moreover, the sprout outgrowth of aortic rings by PDGF-BB was inhibited by cordycepin. In vivo neointimal formation evoked by balloon-injury was significantly attenuated by the administration of cordycepin. These results demonstrate that cordycepin may exert inhibitory effects on PDGF-BB-induced migration and proliferation via interfering with adenosine receptor-mediated NOS pathways, thus resulting in the attenuation of neointima formation. In conclusion, cordycepin may be a potent, promising anti-atherosclerosis agent.
Introduction
Vascular smooth muscle cell (VSMC) migration and proliferation are important cellular processes in the progressive thickening of vessel walls in vascular disorders, including atherosclerosis (1). Platelet-derived growth factor (PDGF) is produced in many cell types, including activated macrophages, VSMCs, and endothelial cells (2) , and regulates VSMC proliferation and migration (3, 4) . PDGF stimulates signaling by enzymes involved in the activation of mitogen-activated protein kinase (MAPK), such as extracellular signal-regulated kinase (ERK) 1/2, p38 MAPK, and stress-activated protein kinase/ c-Jun N-terminal kinase (JNK) (5) . MAPK contributes to the intracellular signal transduction required for cellular functions induced by various stimuli including growth factors (6, 7) . The MAPK pathway mediates PDGF-induced VSMC migration and proliferation (8) . A small heat shock protein (Hsp), Hsp27, a physiological substrate for p38 MAPK, participates in actin cytoskeleton remodeling and the migration and proliferation of various cell types including smooth muscle cells (9) . Moreover, we recently confirmed that this protein plays an important role in PDGF-stimulated VSMC migration (10) .
Cordyceps militaris is an insect-borne fungus in the genus Cordyceps that has been used for herbal remedies and prevention of various diseases (11, 12) . Cordycepin (3'-deoxyadenosine), a nucleoside derivative, is a major component of and was first isolated from C. militaris (13, 14) . Investigations have demonstrated that cordycepin has a variety of pharmacological effects such as antitumorigenic, anti-inflammatory, and antiangiogenic actions (15 -17) . Moreover, previous investigators have reported that cordyceps inhibits the proliferation of various cells, including cancer cells, in vitro (18) . It has been reported that cordycepin stimulates cAMP and cGMP production in platelets (19, 20) . Recently, it has also been shown that cordycepin inhibits the migration and proliferation of VSMC and vascular neointima formation (21) . Moreover, cordycepin inhibits RNA transcription and polyadenylation (22) . Although it can be assumed that cordycepin has an important involvement in vascular diseases (21, 23) , a clear mechanism of function for cordycepin, especially in vascular cell migration, has not been identified to date. In this study, we tested the mechanism of action of cordycepin in vascular disease, in particular in neointima formation.
Materials and Methods

Materials
PDGF-BB was from R&D systems (Minneapolis, MN, USA). Type I collagen from rat tail tendon and matrigel were from BD Bioscience (Minneapolis, MN, USA), and collagenase from Wako (Osaka). H 2 O 2 , 1,3-dipropyl-8-sulphophenylxanthine (DPSPX), and N ω -nitro-Larginine methyl ester (L-NAME) were purchased from Sigma (St. Louis, MO, USA). The following antibodies were used: anti-p38 MAPK, anti-phospho p38 MAPK, anti-ERK1/2, anti-phospho ERK1/2 (Cell signaling, Beverly, MA, USA); anti-phospho Hsp27 (Affinity BioReagents, Golden, CO, USA); and anti-β-actin (Sigma) antibodies. Other chemical reagents were obtained from Amersham-Pharmacia (Piscataway, NJ, USA) or Roche (Basel, Switzerland).
Isolation, identification and purity determination of cordycepin
All experiments were performed in accordance with the institutional guidelines of Konkuk University, Republic of Korea. Cordyceps militaris used in this study was collected from the Chungju-city area and isolated by Dr. S.K. Kim − in the negative mode. The FAB mass spectrum in positive mode revealed the same result. Purity of the isolated cordycepin was found to be 100% when determined by three different HPLC systems.
RASMC isolation and culture
RASMCs (used at passages 5 -8) were enzymatically isolated from male Sprague Dawley (SD) rats (six-weekold, 190 g, n = 4), and cultured in DMEM containing 10% FBS, 100 U/ ml penicillin, 100 μg/ml streptomycin, and 200 mM glutamine. RASMCs were grown to 70% -80% confluence and starved in FBS-free DMEM for 24 h. Cells were grown at 37°C under a humidified 95% air / 5% CO 2 mixture (v/v).
RASMC migration and proliferation assay
Cell migration assays were performed in a 48-well microchemotaxis Boyden chamber (Neuroprobe, Adderbury, Oxon, UK). Proliferation was determined with a 5-bromo-2'-deoxyuridine (BrdU) incorporation assay (Roche, Bedford, MA, USA) (10).
Cell viability assay
To determine RASMC viability, a 2,3-bis [2-methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT) assay was employed using WelCount TM cell viability assay kit (WelGENE, Daegu, South Korea). RASMCs were plated in 96-well plates at a density of 1 × 10 3 cells /well and incubated for 48 h at 37°C, and then XTT was added to each well. Plates were incubated in the presence of XTT dye for 4 h to allow the formation of formazan dye, which was then quantitated at 450 nm with an enzyme-linked immunosorbent assay reader.
Measurement of intracellular ROS generation
O 2 − production was measured using lucigeninenhanced chemiluminescence. After various treatments, RASMCs (3 × 10
5
) were lysed with Tris buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM Na 3 VO 4 , 5 mM NaF, 1% Triton X-100, and 10% glycerol, pH 7.2). The supernatant was treated with 10 μM lucigenin and 500 μM NADPH. After transfection for 5 min, the chemiluminescence was measured repeatedly at 2-min intervals over 20 min using a luminometer (Victor 3; PerkinElmer, Boston, MA, USA). A single value was determined by averaging 7 readings. The values were normalized to the total protein content.
Intracellular H 2 O 2 accumulation in RASMC was measured using the green fluorescence probe 6-carboxy-2',7'-dichlorofluoroscein diacetate (DCF-DA; Molecular Probes, Eugene, OR, USA). RASMCs (1 × 10 6 ) were treated for 10 min with or without PDGF-BB in a 24-well tissue culture plate. The cells were stained with 3 μM DCF-DA at 37°C for 15 min, which allows the rapid oxidization of DCF-DA to the highly fluorescent DCF in the presence of intracellular H 2 O 2 . The immunostained cells were observed with a confocal microscope (Olympus, Melville, NY, USA).
Immunoblotting
Stimulants-stimulated RASMCs (3 × 10
5
) were lysed with cold extraction buffer (20 mM HEPES, pH 7.5, 1% Nonidet P-40, 150 mM NaCl, 10% glycerol, 10 mM NaF, 1 mM Na 3 VO 4 , 2.5 mM 4-nitrophenylphosphate, 0.5 mM PMSF, and 1 tablet of complete proteinase inhibitor cocktail). The cell lysate was centrifuged (16,000 × g, 15 min, 4°C), and the supernatant was collected as the protein sample. The protein concentration was measured using Bio-Rad DC protein assay reagents (Bio-Rad, Hercules, CA, USA). The protein homogenate was diluted (v/v) with SDS sample buffer containing 40 mM Tris-HCl (pH 6.8), 8 mM EGTA, 4% 2-mercaptoethanol, 40% glycerol, 0.01% bromophenol blue, and 4% SDS, and then boiled for 7 min. Proteins (20 -30 μg per lane) were separated on a 10% -14% SDS-polyacrylamide gel and then transferred electrophoretically to a PVDF membrane. The membrane was blocked for 2 h at room temperature with PBS containing 0.05% Tween 20 and 5% fat-free dried milk. The membrane was incubated with antibodies diluted 1:1000 -5000, overnight at 4°C. Immune complexes were detected with horseradish peroxidase-conjugated antibodies diluted 1:1000 and incubated for 1 h at room temperature. The blot was incubated in an enhanced chemiluminescence kit (Amersham-Pharmacia) and exposed to photographic film. The band intensities were measured by computer analysis using Quantitation software (Bio-Rad).
Aortic sprout assay
Ex vivo migration and proliferation of RASMCs were measured by an aortic ring assay using Matrigel with some modifications. The endothelium and adventitium of the aorta from SD rats (5 weeks of age, n = 8) was removed enzymatically, and the vessels were cut into 1-mm rings. The rings were placed and embedded in 48-well plates coated with Matrigel and simultaneously added with PDGF-BB and cordycepin in FBS-free DMEM. In some experiments, embedded rings were incubated in 10% FBS-medium for 5 days. The rings were stained with Diff-Quik (Sysmex Corp, Kobe) and photographed, and the length of sprouts was analyzed by Scion Image software (Scion Corp., Frederick, MD, USA).
Balloon injury and cordycepin administration
SD rats (350 -400 g) were anesthetized using a mixture of ketamine (80 mg/kg) and xylazine (12 mg /kg), and the left common and external carotid arteries were exposed and isolated. A 2F Fogarty catheter (Edwards Lifesciences, Irvine, CA, USA) was introduced into the common carotid artery through an arteriotomy in the external carotid artery and inflated to 1.0 -1.5 atmospheres. A 10-mm injury was induced by withdrawing the catheter 4 times. The external carotid artery was then tied, and the blood flow was restored. After balloon-injury, cordycepin (10 mg/kg per day) was orally injected for 14 days. The control rats received a similar volume of water (2 ml/kg).
Animals were euthanized after 2 weeks and both side carotid arteries were dissected. The arteries were washed in ice-cold PBS and fixed in 2% formalin. Segments from each half were embedded in paraffin; and sections (5 μm) were prepared, cleared with xylene, and hydrated with ethanol. Sections were stained with hematoxylin and eosin and observed with a BX51 light microscope (Olympus, Tokyo). Media and neointima areas of injured arteries were quantified by planimetry (μm 2 ) and intima-to-media ratios were calculated.
Statistical analyses
All data are presented as the mean ± S.E.M. The statistical evaluation of data, using GraphPad prism, version 4.0 (GraphPad Software, La Jolla, CA, USA), was performed by Student's t-tests for comparisons between pairs of groups and by ANOVA for multiple comparisons. P<0.05 was considered statistically significant.
Results
Inhibitory effect of cordycepin on PDGF-BB-induced migration of RASMCs
To determine the effects of cordycepin on vascular responses, we first examined the migration of RASMCs in response to PGDF-BB using the Boyden chamber. PDGF-BB (0.1 -10 ng/ml) dose-dependently increased RASMC migration and this reached a maximum at 10 ng/ml PDGF-BB (Fig. 1A, n = 8) . PDGF-BB (10 ng /ml)-induced migration was inhibited by cordycepin (0.01 -10 μg/ml) in a dose-dependent manner (Fig. 1B,  n = 12) .
To determine the receptor pathways mediated by cordycepin, the effects of cordycepin on RASMC migration induced by PGDF-BB were tested in cells pretreated with a NOS inhibitor and an adenosinereceptor antagonist. Treatment of cells with the NOS inhibitor, L-NAME (100 μM, 60 min) attenuated the cordycepin (10 μg/ ml)-induced inhibition of RASMC migration in response to PDGF-BB (10 ng/ml) ( Fig. 2A) . The A1/A2 adenosine-receptor antagonist DPSPX (10 nM, 60 min) abolished the inhibition of PDGF-BB-induced migration evoked by cordycepin (10 μg/ ml). In contrast, these effects of L-NAME and DPSPX were not observed in resting and PDGF-BB stimulated cells (Fig. 2, n = 7) .
Effect of cordycepin on PDGF-BB-induced RASMC proliferation
The effect of cordycepin on the PDGF-BB-induced proliferation of RASMCs was determined with a BrdU incorporation assay. As shown in Fig. 3A , the treatment of RASMCs with PDGF-BB (0.1 -10 ng/ml) induced an increase in proliferation, and this reached a maximum at 10 ng/ml PDGF-BB (n = 12). The pretreatment of RASMCs with cordycepin (0.01 -10 μg/ml) dosedependently inhibited PDGF-BB (10 ng/ml)-induced proliferation. This inhibition began at a concentration of 0.01 μg/ ml cordycepin. At higher concentrations of cordycepin, proliferation of RASMCs was inhibited to a level lower than the basal level of proliferation (Fig. 3B, n = 12) . Because cordycepin inhibited RASMC proliferation to levels lower than basal levels, it can be assumed that cordycepin has cytotoxic effects on cells. Whether cordycepin affects RASMC viability was determined using the XTT assay and direct cell counting. As shown in Fig. 3C , RASMC viability was not altered by treatment with cordycepin (0.01 -10 μg/ml, n = 12). Similar results were obtained from direct cell counting (data not shown).
Effects of cordycepin on ROS production
PDGF induces intracellular responses via the ROSdependent pathway. Therefore, the effect of cordycepin on ROS production was measured. H 2 O 2 (10, 100 μM) stimulated the migration of RASMCs in a dose- dependent manner (n = 5, Fig. 4A ). PDGF-BB (10 ng/ml) increased O 2 − production, which was inhibited by cordycepin (1 μg/ml) (n = 7, Fig. 4B ). Similarly, cordycepin (1 μg/ml) inhibited the production of H 2 O 2 increased by PDGF-BB in RASMC (Fig. 5B, n = 6 ).
Effect of cordycepin on PDGF-BB-stimulated kinase activity in RASMCs
To clarify how PDGF-BB-induced responses were affected by cordycepin, we analyzed the effects of cordycepin on the activity of kinases in RASMCs. The kinase activities were measured using phosphospecific antibodies. The phosphorylation of p38 MAPK, ERK1/ 2, and Hsp27 in RASMCs were increased by treatment with PDGF-BB (Fig. 5A) . PDGF-BB (10 ng /ml)-induced phosphorylation of p38 MAPK was inhibited by cordycepin (0.01 -10 μg/ ml) in a dosedependent manner (Fig. 5B, n = 4) . Similarly, the phosphorylation of Hsp27 in response to PDGF-BB was abolished by cordycepin (0.01 -10 µg/ml) (Fig. 5C , n = 4). In contrast, ERK1/2 phosphorylation induced by PDGF-BB was not attenuated by treatment with cordycepin (Fig. 5D, n = 4) .
Effects of cordycepin on the formation of aortic sprouts
To determine the role of migration and proliferation ex vivo, we analyzed the effect of cordycepin on the PDGF-BB-induced response in the aortic rings using Matrigel. As shown in Fig. 6A , PDGF-BB (10 ng /ml) increased the formation of sprout outgrowth from aortic rings. The treatment of aortic rings with cordycepin After treatment with L-NAME (100 μM), DPSPX (10 nM), and /or cordycepin (10 μg/ ml), the cells were loaded into the upper chamber containing PDGF-BB (10 ng /ml) and incubated for 90 min (n = 7), as described in the Methods section. *P<0.05 and # P<0.05 vs. the PDGF-BB and PDGF-BB plus cordycepin-induced responses, respectively. Fig. 3 . Effect of cordycepin on proliferation in RASMCs. A: Effect of PDGF-BB on RASMC proliferation. RASMCs were treated with PDGF-BB for 24 h (n = 12). Cell proliferation was quantified using a bromodeoxyuridine incorporation assay. *P<0.05 vs. the quiescent state. B: Effect of cordycepin on PDGF-induced proliferation in RASMCs. RASMCs were treated with cordycepin (0.01 -10 μg/ml) and then stimulated with PDGF-BB (10 ng / ml) for 24 h. Proliferation in the quiescent state was deemed to be 100% (n = 12) *P<0.05 vs. the PDGF-BBinduced responses. C: Effects of cordycepin on RASMC viability. RASMCs were treated with cordycepin (0.01 -10 µg/ml) for 60 min. Cell viability was quantified using the XTT assay. Cell viability in the quiescent state was considered to be 100% (n = 12).
(0.01 -10 μg/ml) dose-dependently inhibited PDGF-BB-induced sprouts of aortic rings (Fig. 6B, n = 4) .
Effects of cordycepin on neointima formation
To investigate the effect of cordycepin on neointimal formation in carotid arteries, we used a model of neointimal formation in balloon-injured arteries. Administration of cordycepin (10 mg/kg per day) for 14 days markedly decreased neointimal formation. The intima /media (I/ M) ratio was significantly reduced in cordycepin-treated carotid arteries compared with balloon-injured carotid arteries from control rats (Fig. 6 : C and D, n = 6).
Discussion
Adenosine receptor subtypes, A 1 , A 2a , A 2b , and A 3 , are implicated in a variety of cell functions. A 1 /A 2 receptors are widely expressed in vascular cells and exert cardioprotective effects (24) . Treatment with adenosine inhibits vascular cell proliferation via A 2b receptor activation (25, 26) . Moreover, vascular neointima formation is inhibited by an A 2 -receptor agonist (27) and is increased in the A 2b receptor-knockout mouse (24) , implying that the A 2b receptor is negatively involved in vascular disorders, including neointima formation. In this study, we found that cordycepin induced inhibition of cell migration, which was significantly recovered by A 1 /A 2 receptor antagonists. These results show that cordycepin inhibits vascular migration via A 1 /A 2 -receptor activation. Moreover, in this study, the treatment of cells with cordycepin diminished the production of ROS, O 2 − , and H 2 O 2 in RASMCs. It is known that ROS participates in the migration of VSMCs (10, 28) and is involved in PDGF-induced neointima formation (4). Moreover, the present results show that H 2 O 2 increases VSMC migration. In this study, cordycepininduced inhibition of migration was recovered by the NOS inhibitor L-NAME in RASMCs. Cordycepin increased the activity of NOS and production of NO and elevated production of cAMP and cGMP in platelets (19, 20) , implying that effects of cordycepin may be mediated by NO production in RASMCs. Furthermore, NO acts as a ROS scavenger and transiently forms ONOO − , which consequently results in the diminution of ROS levels (29) . ONOO − increased the formation of cGMP and decreased the phosphorylation of MAPK, including p38 MAPK, in vascular smooth muscle cells Fig. 4 . Effects of cordycepin on PDGF-BB-induced ROS production. A: H2O2-induced migration. The cells were treated with H2O2 (10, 100 μM) for 90 min and migration was examined using the Boyden chamber assay. The migration of RASMCs in the quiescent state was expressed as 100% (n = 5). *P<0.05 vs. the quiescent state. B: O2
− production in PDGF-BB (10 ng /ml)-stimulated cells was measured using a lucigenin-enhanced chemiluminescence assay as described in the Methods section (n = 7). C: Intracellular H2O2 generation in response to PDGF-BB (10 ng / ml) was measured using the green fluorescence probe DCF-DA. D: The statistical results obtained from panel C (n = 6). *P<0.05 vs. PDGF-stimulated state.
(30). These results suggest that NO production by cordycepin via the adenosine receptor acts as an inhibitory mediator on ROS-associated PDGF responses. This study is the first to demonstrate the molecular mechanism of cordycepin-induced inhibition on VSMC neointima formation and vascular sprout outgrowth in response to PDGF.
MAPKs play important roles in a variety of cellular functions (6) . Proliferation and migration are associated with the phosphorylation of MAPKs in VSMCs (31, 32) . MAPKs mediate migration and proliferation in response to PDGF in VSMCs (8, 10) . Moreover, ROS participates in the activation of MAPK in vascular smooth muscle (33) . Our previous report showed that the inhibition of MAPK abolishes aortic sprout outgrowth, RASMC migration, and proliferation in response to PDGF (10) . Furthermore, Hsp27 is expressed in many cell types and its phosphorylation is important for actin cytoskeleton remodeling and PDGF-induced smooth muscle cell migration (9, 10) . In our previous study, PDGF enhanced the phosphorylation of p38 MAPK and Hsp27, and PDGF-induced migration in VSMCs was attenuated by the inhibition of p38 MAPK activity and the cell transfection of small interference RNA-Hsp27 (11), indicating that p38 MAPK is an upstream molecule of Hsp27. In this study, PDGF-BB increased RASMC migration and cordycepin inhibited PDGF-enhanced cell migration, p38 MAPK, and Hsp27 phosphorylation in RASMCs. Therefore, our results demonstrate that the PDGF-induced phosphorylation of p38 MAPK and Hsp27 is suppressed by treatment with cordycepin, which may be involved in PDGF-induced migration in RASMCs. These data indicate that cordycepin exhibits its inhibitory effects on RASMC migration and proliferation via the suppression of p38 MAPK and Hsp27 phosphorylation that is elevated by ROS in response to PDGF. Furthermore, ERK1/2 acts as a contributor in PDGF-induced migration and proliferation (8, 33) . In this study, cordycepin did not suppress the level of ERK1/ 2 phosphorylation in response to PDGF, implying that the inhibitory effects of cordycepin on proliferation and migration may not be involved in ERK1/ 2 activity. These results suggest that MAPK isoforms may be regulated differently by cordycepin.
The present results show that the treatment of cordycepin attenuated PDGF-enhanced migration and proliferation in RASMCs. The proliferation and migration of medial smooth muscle cells are important processes for vascular neointimal formation. Cordycepin also abolished the sprout outgrowth of the aorta, which is consistent with VSMC proliferation and migration. These results imply that cordycepin may exert inhibitory effects on neointima formation, which may result from the suppression of proliferation and migration in VSMCs. Cordyceps have various properties, including inhibition of tumorigenesis and inflammation (34, 35) . Although the cell type is different from the previous study, cordycepin inhibited the proliferation of leukemia cells (36) . In this study, cordycepin abolished cell proliferation, which reached to a level lower than the basal state. It is known that cordycepin affects to cell proliferation via its inhibitory effects on RNA transcription and polyadenylation (22) . These results imply that cordycepin is a potent inhibitor of cell proliferation. Moreover, the effects of cordycepin on the vascular system have also been examined (21) . Cordyceps have been widely used as a traditional medicine to protect individuals from cardiovascular diseases in the Oriental countries (23) . In this study, we determined the effects of cordycepin and its mechanism of action in the vascular system. Our findings, therefore, indicate that cordycepin may act as a candidate in preventing cardiovascular disorders including arterial remodeling and this may offer useful information for developing herbal remedies for vascular disorders, especially atherosclerosis.
In summary, we found that cordycepin inhibited the phosphorylation level of p38 MAPK and Hsp27 in RASMCs stimulated by PDGF-BB. Moreover, cordycepin inhibited the ROS levels and migration in RASMCs elevated by PDGF-BB. These inhibitory effects of cordycepin were prevented by an adenosine-receptor antagonist and a NOS inhibitor. In vivo and ex vivo administration of cordycepin inhibited the formation of neointima by balloon injury and aortic sprout outgrowth in response to PDGF-BB. From these results, we concluded that the inhibitory effects of cordycepin on the p38 MAPK and Hsp27 pathways results in the inhibition of VSMC migration and proliferation, which may be mediated by adenosine receptor-induced NOS activation. We suggest, therefore, that cordycepin could be a good candidate for developing herbal remedies that can serve as potential antiatherosclerotic agents.
